Pegylated interferon-α-2a and ribavirin

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)